Ipamorelin
Ipamorelin is a selective growth hormone–releasing peptide (GHRP) researched for its targeted action and reduced impact on non-GH pathways.
Key Research Points:
Studied for selective GH release with minimal cortisol or prolactin involvement
Explored in muscle recovery and body composition research
Often researched in combination with GHRH analogs
Short-acting peptide used in controlled laboratory studies
For research and laboratory use only
Ipamorelin binds to the growth hormone secretagogue receptor (GHSR-1a) and stimulates the pituitary gland to release endogenous growth hormone in a pulsatile manner. Unlike earlier growth hormone releasing peptides, ipamorelin is highly selective and does not significantly stimulate ACTH, cortisol, or prolactin release at effective doses. After subcutaneous injection, GH levels peak within approximately 40 minutes and return to baseline by 2–3 hours. This short-acting pulsatile effect makes it suitable for once-daily administration to support physiological GH patterns. Animal studies have shown that even chronic daily exposure did not significantly desensitize GH release mechanisms[5], though cycling is recommended as a precautionary measure. Ipamorelin has also demonstrated pro-motility effects in the gastrointestinal tract via GHSR-1a receptors, with preclinical and clinical studies showing it can accelerate gastric emptying.